DBH gene as predictor of response in a cocaine vaccine clinical trial

Neuroscience Letters

Volumn 541, Issue , 2013, Pages 29-33

  Kosten, Thomas R ^a   Domingo, Coreen B ^a   Hamon, Sara C ^b   Nielsen, David A ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b ROCKEFELLER UNIVERSITY   (United States)

Author keywords

Cocaine; Dopamine; Gene; Polymorphism; Treatment; Vaccine

Indexed keywords

COCAINE; COCAINE VACCINE; DOPAMINE BETA MONOOXYGENASE; DRUGS USED IN THE TREATMENT OF ADDICTION; UNCLASSIFIED DRUG; VACCINE;

ADULT; ARTICLE; COCAINE DEPENDENCE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG RESPONSE; FEMALE; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; PHARMACOGENOMICS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; URINALYSIS; URINE LEVEL;

ADOLESCENT; ADULT; CHOLERA TOXIN; CLINICAL TRIALS, PHASE II AS TOPIC; COCAINE; COCAINE-RELATED DISORDERS; DOPAMINE BETA-HYDROXYLASE; FEMALE; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; VACCINES; YOUNG ADULT;

EID: 84876406559     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2013.02.037     Document Type: Article

References (51)

1. A.P.Association, American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders 2000, American Psychiatric Association, Washington, DC. fourth edition, text revision.
2. Baker J.R., Jatlow P., McCance-Katz E.F. Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend. 2007, 87:202-209.
3. Bhaduri N., Mukhopadhyay K. Correlation of plasma dopamine beta-hydroxylase activity with polymorphisms in DBH gene: a study on eastern Indian populaion. Cell. Mol. Neurobiol. 2008, 28:343-350.
4. Carboni E., Tanda G.L., Frau R., Di Chiara G. Blockade of the noradrenaline carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that dopamine is taken up in vivo by noradrenergic terminals. J. Neurochem. 1990, 55:1067-1070.
5. Carroll K.M. Manual-guided psychosocial treatment. A new virtual requirement for pharmacotherapy trials?. Arch. Gen. Psychiatry 1997, 54:923-928.
6. Carroll K.M., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., Rounsaville B.J. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: a randomized placebo-controlled trial. Arch. Gen. Psychiatry 2004, 61:264-272.
7. Cubells J.F., Kranzler H.R., McCance-Katz E., Anderson G.M., Malison R.T., Price L.H., Gelernter J. A haplotype at the DBH locus, associated with low plasma dopamine beta-hydroxylase activity, also associates with cocaine-induced paranoia. Mol. Psychiatry 2000, 5:56-63.
8. Cubells J.F., van Kammen D.P., Kelley M.E., Anderson G.M., O'Connor D.T., Price L.H., Malison R., Rao P.A., Kobayashi K., Nagatsu T., Gelernter J. Dopamine beta-hydroxylase: two polymorphisms in linkage disequilibrium at the structural gene DBH associate with biochemical phenotypic variation. Hum. Genet. 1998, 102:533-540.
9. Cubells J.F., Zabetian C.P. Human genetics of plasma dopamine beta-hydroxylase activity: applications to research in psychiatry and neurology. Psychopharmacology (Berl.) 2004, 174:463-476.
10. de Wit H. Priming effects with drugs and other reinforcers. Exp. Clin. Psychopharmacol. 1996, 4:5-10.
11. deLeon J., Armstrong S.C., Cozza K.L. Clinical guidelines for psychiatrists for the use of pharmacogenetic testing for CYP450 and CYP450 2C19. Psychosomatics 2006, 47:75-85.
12. Dutra L., Stathopoulou G., Basden S.L., Leyro T.M., Powers M.B., Otto M.W. A meta-analytic review of psychosocial interventions for substance use disorders. Am. J. Psychiatry 2008, 165:179-187.
13. Goldman D., Oroszi G., Ducci F. The genetics of addictions: uncovering the genes. Nat. Rev. Genet. 2005, 6:521-532.
14. Haile C.N., During M.J., Jatlow P.I., Kosten T.R., Kosten T.A. Disulfiram facilitates the development and expression of locomotor sensitization to cocaine in rats. Biol. Psychiatry 2003, 54:915-921.
15. Hameedi F.A., Rosen M.I., McCance-Katz E.F., McMahon T.J., Price L.H., Jatlow P.I., Woods S.W., Kosten T.R. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol. Psychiatry 1995, 37:560-563.
16. Haney M., Gunderson E.W., Jiang H., Collins E.D., Foltin R.W. Cocaine-specific antibodies blunt the subjective effects of smoked cocaine in humans. Biol. Psychiatry 2010, 67:59-65.
17. Hubisz M.J., Falush D., Stephens M., Pritchard J.K. Inferring weak population structure with the assistance of sample group information. Mol. Ecol. Resour. 2009, 9:1322-1332.
18. Jonsson E.G., Bah J., Melke J., Abou Jamra R., Schumacher J., Westberg L., Ivo R., Cichon S., Propping P., Nothen M.M., Eriksson E., Sedvall G.C. Monoamine related functional gene variants and relationships to monoamine metabolite concentrations in CSF of healthy volunteers. BMC Psychiatry 2004, 4:4.
19. Kalayasiri R., Sughondhabirom A., Gueorguieva R., Coric V., Lynch W.J., Lappalainen J., Gelernter J., Cubells J.F., Malison R.T. Dopamine beta-hydroxylase gene (DbetaH) -1021C→T influences self-reported paranoia during cocaine self-administration. Biol. Psychiatry 2007, 61:1310-1313.
20. Kohnke M.D., Zabetian C.P., Anderson G.M., Kolb W., Gaertner I., Buchkremer G., Vonthein R., Schick S., Lutz U., Kohnke A.M., Cubells J.F. A genotype-controlled analysis of plasma dopamine beta-hydroxylase in healthy and alcoholic subjects: evidence for alcohol-related differences in noradrenergic function. Biol. Psychiatry 2002, 52:1151-1158.
21. Kosten T., Wu G., Huang W., Harding M.J., Hamon S.C., Lappalainen J., Nielsen D.A. Pharmacogenetic randomized trial for cocaine abuse: disulfiram and dopamine β-hydroxylase. Biol. Psychiatry 2013, 73:219-224.
22. Kosten T.R., Rosen M., Bond J., Settles M., Roberts J.S., Shields J., Jack L., Fox B. Human therapeutic cocaine vaccine: safety and immunogenicity. Vaccine 2002, 20:1196-1204.
23. Laje G., McMahon F.J. The pharmacogenetics of major depression: past, present, and future. Biol. Psychiatry 2007, 62:1205-1207.
24. Lao O., van Duijn K., Kersbergen P., de Knijff P., Kayser M. Proportioning whole-genome single-nucleotide-polymorphism diversity for the identification of geographic population structure and genetic ancestry. Am. J. Hum. Genet. 2006, 78:680-690.
25. Leshner A.I. Addiction is a brain disease, and it matters. Science 1997, 278:45-47.
26. Malhotra A.K., Murphy G.M., Kennedy J.L. Pharmacogenetics of psychotropic drug response. Am. J. Psychiatry 2004, 161:780-796.
27. Martell B.A., Mitchell E., Poling J., Gonsai K., Kosten T.R. Vaccine pharmacotherapy for the treatment of cocaine dependence. Biol. Psychiatry 2005, 58:158-164.
28. Martell B.A., Orson F.M., Poling J., Mitchell E., Rossen R.D., Gardner T., Kosten T.R. Cocaine vaccine for the treatment of cocaine dependence in methadone-maintained patients: a randomized, double-blind, placebo-controlled efficacy trial. Arch. Gen. Psychiatry 2009, 66:1116-1123.
29. McCance-Katz E.F., Kosten T.R., Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: initial results. Biol. Psychiatry 1998, 43:540-543.
30. McCance-Katz E.F., Kosten T.R., Jatlow P. Disulfiram effects on acute cocaine administration. Drug Alcohol Depend. 1998, 52:27-39.
31. McLellan A.T., Lewis D.C., O'Brien C.P., Kleber H.D. Drug dependence a chronic medical illness: implications for treatment, insurance, and outcomes evaluation. JAMA 2000, 284:1689-1695.
32. McLellan A.T., Luborsky L., Woody G.E., O'Brien C.P. An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J. Nerv. Ment. Dis. 1980, 168:26-33.
33. Murphy G.M., Kremer C., Rodrigues H.E., Schatzberg A.F. Pharmacogenetics of antidepressant medication intolerance. Am. J. Psychiatry 2003, 160:1830-1835.
34. Orson F.M., Kinsey B.M., Singh R.A., Wu Y., Gardner T., Kosten T.R. Substance abuse vaccines. Ann. N.Y. Acad. Sci. 2008, 1141:257-269.
35. Oxenstierna G., Edman G., Iselius L., Oreland L., Ross S.B., Sedvall G. Concentrations of monoamine metabolites in the cerebrospinal fluid of twins and unrelated individuals-a genetic study. J. Psychiatr. Res. 1986, 20:19-29.
36. Paula S., Tabet M.R., Farr C.D., Norman A.B., Ball W.J. Three-dimensional quantitative structure-activity relationship modeling of cocaine binding by a novel human monoclonal antibody. J. Med. Chem. 2004, 47:133-142.
37. Pritchard J.K., Stephens M., Rosenberg N.A., Donnelly P. Association mapping in structured populations. Am. J. Hum. Genet. 2000, 67:170-181.
38. R_Development_Core_Team R: A Language and Environment for Statistical Computing 2009, R Foundation for Statistical Computing, Vienna, Austria.
39. Rogers J.F., Nafziger A.N., Bertino J.S.J. Pharmacogenetics affects dosing, efficacy, and toxicity of cytochrome P450-metabolized drugs. Am. J. Med. 2002, 113:746-750.
40. Ross S.B., Wetterberg L., Myrhed M. Genetic control of plasma dopamine-beta-hydroxylase. Life Sci. 1973, 12:529-532.
41. SAMSHA, in: N.S. H-41 (Ed.), Results from the 2010 National Survey on Drug Use and Health (NSDUH), Rockville, MD, 2011.
42. Schank J.R., Liles L.C., Weinshenker D. Norepinephrine signaling through beta-adrenergic receptors is critical for expression of cocaine-induced anxiety. Biol. Psychiatry 2008, 63:1007-1012.
43. Schank J.R., Ventura R., Puglisi-Allegra S., Alcaro A., Cole C.D., Liles L.C., Seeman P., Weinshenker D. Dopamine beta-hydroxylase knockout mice have alterations in dopamine signaling and are hypersensitive to cocaine. Neuropsychopharmacology 2006, 31:2221-2230.
44. Simpson D.D., Joe G.W., Broome K.M. A national 5-year follow-up of treatment outcomes for cocaine dependence. Arch. Gen. Psychiatry 2002, 59:538-565.
45. Sofuoglu M., Kosten T.R. Emerging pharmacological strategies in the fight against cocaine addiction. Expert Opin. Investig. Drugs 2006, 11:91-98.
46. Tanda G., Pontieri F.E., Frau R., Di Chiara G. Contribution of blockade of the noradrenaline carrier to the increase of extracellular dopamine in the rat prefrontal cortex by amphetamine and cocaine. Eur. J. Neurosci. 1997, 9:2077-2085.
47. Wei J., Ramchand C.N., Hemmings G.P. Possible control of dopamine beta-hydroxylase via a codominant mechanism associated with the polymorphic (GT)n repeat at its gene locus in healthy individuals. Hum. Genet. 1997, 99:52-55.
48. Weinshilboum R.M., Raymond F.A., Elveback L.R., Weidman W.H. Serum dopamine-beta-hydroxylase activity: sibling-sibling correlation. Science 1973, 181:943-945.
49. Weisner C., Matzger H., Kaskutas L.A. How important is treatment? One-year outcomes of treated and untreated alcohol-dependent individuals. Addiction 2003, 98:901-911.
50. Zabetian C.P., Anderson G.M., Buxbaum S.G., Elston R.C., Ichinose H., Nagatsu T., Kim K.S., Kim C.H., Malison R.T., Gelernter J., Cubells J.F. A quantitative-trait analysis of human plasma-dopamine beta-hydroxylase activity: evidence for a major functional polymorphism at the DBH locus. Am. J. Hum. Genet. 2001, 68:515-522.
51. Zabetian C.P., Buxbaum S.G., Elston R.C., Kohnke M.D., Anderson G.M., Gelernter J., Cubells J.F. The structure of linkage disequilibrium at the DBH locus strongly influences the magnitude of association between diallelic markers and plasma dopamine beta-hydroxylase activity. Am. J. Genet. 2003, 72:1389-1400.